Verona Pharma (VRNA, $13) was a top loser over the last three months, falling -2 to $13 per share. A.I.dvisor analyzed 903 stocks in the Biotechnology Industry for the 3-month period ending May 17, 2024, and found that of them (3) exhibited an Uptrend while of them (6) demonstrated a Downtrend.